Goldberg A, Sweet C
Efficacy and safety of losartan
Can J Cardiol (Suppl. F)
(Aug) 11:F27-F32 1995
Losartan is the first clinically available AII blocker for use in
hypertension. The efficacy and safety of this agent have been assessed in
approx. 3700 patients in double-blind controlled trials. The BP lowering
effect
of losartan 50 mg qd was similar to 20 mg qd of enalapril. Addition of 12.5
mg Hctz increased antihypertensive response. Dizziness was the most common
side effect with an incidence above that of placebo (2.4% vs. 1.3%).
Withdrawal from losartan occurred in only 2.3% vs. 3.7% of patients. on
placebo.
The incidence of cough was 3.1% with losartan vs. 2.6% with placebo (NS) and
significantly lower than with ACE inhibitors (8.8%). Hyperkalemia occurred
in 1.5% of losartan-treated patients. and in 1.3% of patients on ACE
inhibitors. No
significant drug interactions were noted. Losartan is an effective and safe
agent for hypertension and will be especially useful in patients unable to
tolerate ACE inhibitors.
(Leehey)
To go back use the BACK button on your browser.
Otherwise click on the desired link to this article below:
H: Drug therapy :
ACE inhibitors